UPDATE: COLCORONA study manuscript is now available in the public domain.
Read the manuscript
On January 22, 2021, the Montreal Heart Institute announced positive results from COLCORONA trial. These results showed that colchicine is the only effective oral medication for treating non-hospitalized patients.
The trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo. This result obtained for the global study population of 4488 patients approached statistical significance. The analysis of the 4159 patients in whom the diagnosis of COVID-19 was proven by a naso-pharyngeal PCR test has shown that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo. In these patients with a proven diagnosis of COVID-19, colchicine reduced hospitalizations by 25%, the need for mechanical ventilation by 50%, and deaths by 44%. This major scientific discovery makes colchicine the world’s first oral drug that could be used to treat non-hospitalized patients with COVID-19.
Read the press release
Your contributions allow us to look to the future and innovate. Thank you for continuing to make a difference by supporting our foundation.
Donate today
These articles might interest you:
- Colchicine: a new ally for cardiovascular health
- COLCORONA genetic study: better understanding the symptoms of COVID-19
- Questions and answers: COVID-19 and cardiovascular health
Dr. Jean-Claude Tardif, Director of the MHI Research Center, Professor of Medicine at the Université de Montréal and Principal Investigator of the COLCORONA trial
© Montreal Heart Institute, 2021
The Montreal Heart Institute authorizes the reproduction of the COLCORONA study results on the effects of colchicine for public purposes provided that the sources of it, namely the Montreal Heart Institute and the authors, are clearly cited on all such reproductions and that no material modification be made to the original published text without its express consent. The COLCORONA trademark is owned by the Montreal Heart Institute and may not be used without its prior written consent.